{"filings":[{"id":94036,"accession_number":"0001628280-26-032101","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.","Net loss $85.1M ($0.60/sh) vs $66.9M ($0.50) prior year; positive cash inflow $11.8M.","Raises FY2026 revenue guidance by $120M midpoint to $2.74B-$2.82B; gross margin expected 64%-66%.","Operating expenses $538.6M (+36.0%) on headcount growth and clinical trial expenses.","Cash and equivalents $1,087.9M; debt $80.3M under line of credit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":696644000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94035,"accession_number":"0001104659-26-038519","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Eric Rubin to Board, increasing size to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Rubin appointed as independent Class I director effective March 26, 2026; term expires at 2028 annual meeting.","Board size increased from 10 to 11 members; Rubin joins the Nominating, Corporate Governance and Compliance Committee.","Initial equity award vests in three equal installments on March 26, 2027, 2028, and 2029.","Standard non-employee director cash and equity compensation; indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106104,"accession_number":"0001104659-26-020482","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).","Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.","Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.","Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).","FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2306113000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106103,"accession_number":"0001104659-26-002861","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.","Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.","Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).","Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2306113000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122393,"accession_number":"0001104659-25-118664","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.","Adds Foresight's PhasED-Seq phased variant technology with LOD95 of 0.3 ppm, enhancing Signatera MRD platform.","Expands Natera's presence in lymphoma, with Foresight's CLARITY MRD assay used in three prospective trials and NCCN guideline inclusion.","Integration of phased variants into Signatera platform expected to be launched for clinical use in 2026.","Company issued 1,127,982 shares upfront and up to ~824,583 additional contingent shares; will file registration for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122392,"accession_number":"0001104659-25-107727","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.","Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.","Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.","Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.","FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1640615000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139100,"accession_number":"0001104659-25-075189","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).","Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).","Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.","Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.","Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1048431000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156613,"accession_number":"0001104659-25-060626","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Natera stockholders approve 3.6M share equity plan increase and reelect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Baynes, Marcus, and Williams-Brinkley reelected with 91.0M, 79.7M, and 109.0M votes for, respectively.","Ernst & Young ratified as auditor for FY2025: 116.8M for, 0.7M against.","Advisory vote on named executive officer compensation passed: 107.8M for, 4.6M against.","Amendment to 2015 Equity Incentive Plan adding 3.6M shares approved: 83.3M for, 29.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156612,"accession_number":"0001104659-25-046121","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).","Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).","Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.","Positive operating cash flow $23.2M; cash & investments $991.6M.","Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":501830000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175036,"accession_number":"0001104659-25-022968","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Monica Bertagnolli to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11; Bertagnolli appointed as Class III director, term expiring at 2027 annual meeting.","She previously served from Nov 2020 to Aug 2022 before becoming Director of the National Cancer Institute.","She is independent and appointed to Nominating, Corporate Governance and Compliance Committee.","Compensation consistent with other non-employee directors; initial equity award vests over three years.","Indemnification agreement entered into with Bertagnolli."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175035,"accession_number":"0001104659-25-018223","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).","Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.","Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.","Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).","FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1696911000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175034,"accession_number":"0001104659-25-002846","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.","Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.","Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.","Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.","Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1696911000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191997,"accession_number":"0001104659-24-126348","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Natera amends employment agreement for Executive Chairman Matthew Rabinowitz","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rabinowitz's base salary set at 50% of CEO's base salary, with annual cash bonus up to 85% of base salary.","Annual equity awards valued at 80% of CEO's annual equity grants, split between time-based and performance-based vesting.","Severance includes lump-sum cash of 12 months' base salary (18 months if within 12 months of change in control) plus COBRA premiums for 12 months (18 months for CIC).","Time-based equity accelerates upon involuntary termination: greater of 50% of unvested shares or 12 months forward vesting; full acceleration upon CIC.","Performance-based equity awards granted after effective date vest based on actual performance multiplied by service fraction plus 12 months; CIC triggers greater of actual or 100% achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191996,"accession_number":"0001104659-24-116777","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.","Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).","Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.","2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.","Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1220850000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208467,"accession_number":"0001104659-24-087273","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.","Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.","Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.","Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.","Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":781092000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208466,"accession_number":"0001104659-24-081215","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Natera to redeem all $287.5M of 2.25% Convertible Notes due 2027 on Oct 11","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Natera elects to redeem all $287.5M aggregate principal of its 2.25% Convertible Senior Notes due 2027.","Redemption date set for October 11, 2024; price is 100% of principal plus accrued interest to that date.","Trustee instructed to issue redemption notice to registered holders; optional redemption right exercised by company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226147,"accession_number":"0001104659-24-072800","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Natera shareholders approve amended equity plan adding 6M shares; director Botha reelected narrowly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2015 Equity Incentive Plan approved with 85.9M for, 21.5M against; adds 6M shares, extends term 10 years, removes evergreen feature.","Director Roelof Botha reelected with 54.5M for, 53.0M withheld — a 50.7% majority vote.","Directors Chapman (106.5M for) and Rabinowitz (102.5M for) easily elected; auditor Ernst & Young ratified (114.3M for).","Advisory say-on-pay approved with 101.6M for, 5.9M against.","Total outstanding shares 123.2M; quorum 114.7M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226146,"accession_number":"0001104659-24-059333","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.","Net loss $67.6M ($0.56/share) vs $136.9M ($1.23/share) YoY; achieved ~$3M positive cash flow.","Processed ~735,800 tests (+17.5%); oncology tests ~114,800 (+61.7%).","Launched fetal RhD NIPT test; published key data in oncology and organ health.","FY 2024 guidance: revenue $1.42B-$1.45B; gross margin 53-55%; net cash ($25M)-$25M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":367741000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245226,"accession_number":"0001104659-24-028724","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.","Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).","Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.","Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.","FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1082571000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}